The FDA has approved Ambelvist, a macrocyclic gadolinium-based option for contrast-enhanced MRI, now the lowest ...
Bayer today announced that the U.S. Food and Drug Administration (FDA) approved AMBELVIST® (gadoquatrane), a new, intravenous macrocyclic gadolinium (Gd)-based contrast agent (mGBCA) indicated for ...
The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools.
Reveal's New Manganese-Based MRI Contrast Agent Advances Safer Patient Care · globenewswire.com CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Contrast agents used in MRI scans to improve the ...
People with a history of allergic-like reactions to iodinated contrast media, which is used in a variety of X-ray-based procedures, such as CT and angiography, are susceptible to similar reactions ...
You can keep your best guesses. Engineers at Rice University's George R. Brown School of Engineering are starting to understand exactly what goes on when doctors pump contrast agents into your body ...
Contrast agents used to improve views of the heart on MRI carry a very low risk of allergic reactions, vomiting and other acute adverse events, according to a large study from Europe published in ...
The FDA has approved Bayer’s Ambelvist (gadoquatrane), the lowest-dose macrocyclic GBCA for adult and pediatric contrast-enhanced CNS and body MRI exams.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results